"Avoidable Deaths" - Union for International Cancer Control

"Back to Basics: The Concept of HRQL Under a Magnifying Glass" - EORTC Quality of Life Group

"Bald for a Cause" initiative - UWC Dilijan College

Jasmin Hundal: How Lifestyle Medicine Can Be Integrated into Oncology Care

Rahul Banarjee: Thanks ASCO ASCO TECAG for letting Dionisia Quirog and me talk about the who /what / when/ where/ why/ how of oncology boards for current fellows

QUANTRO Therapeutics secures Austrian research grant to accelerate development of their platform

NCI Division of Cancer Prevention - Early Career Scientist Seminar with Dr. Venkateshwar Madka

Giannis Mountzios: Amazing 1st day of the ESMO Advanced Course in Early-Stage NSCLC

Johanna Joyce: Check out the new Ludwig Leadership Fellows Program

NSCLC

Nov 27, 2023

Insight

Vivek Subbiah: Treatment patterns and overall survival (OS) in patients with advanced NSCLC in three countries between 2011 and 2020

Nov 18, 2023

Opinion

Aakash Desai: Tune in to our podcast episode for an in-depth dive into HER3 therapy’s development and clinical possibilities

Nov 12, 2023

Drugs

David Planchard: Thank you to the patients who actively participated in this research

Nov 1, 2023

Insight

Alessandro Inno: A case of a very elderly patient with MET-exon 14 mutant NSCLC with meaningful and durable benefit from first-line tepotinib, with an acceptable safety profile

Oct 29, 2023

Drugs

Antonio Passaro: I was honored to present in Presidential, the primary results of the global randomized phase 3 study MARIPOSA-2

Oct 27, 2023

Insight

The first randomised trial of a targeted agent versus immunotherapy plus chemotherapy in a biomarker-selected patient population – CUHK Medicine

Oct 23, 2023

Insight

Marcelo Corassa: Great presentation by the amazing Jarushka Naidoo on the promises and pitfalls of neoadjuvant therapy for NSCLC

Oct 22, 2023

Blog Posts

Giulio Draetta: Tremendously proud of Tina Cascone for her presentation at the 2023 ESMO meeting presidential session

Oct 21, 2023

Blog Posts

Jose Fernando Moura: Phase 2 PERLA trial shows a new option in same setting NSCLC 1st line.

Sep 30, 2023

Insight

Oscar Arrieta: Our study demonstrated that increased perilesional edema from brain metastases from NSCLC is a negative predictor of response to radiation therapy, short intracranial-PFS, and even worse OS.